EGFR-Mutated mNSCLC: Evolving Treatment Strategies and Post-ESMO 2025 Clinical Insights

In this OncLive® NewsNetwork Presents discussion, Narjust Florez, MD, and Julia Rotow, MD, from Dana-Farber Cancer Institute, provide expert insight into the latest ESMO 2025 data on EGFR-mutated metastatic non–small cell lung cancer (mNSCLC). Through a dynamic, case-oriented dialogue, the experts review new analyses from pivotal studies—including FLAURA2, MARIPOSA, COMPEL, and PALOMA-2—that are reshaping frontline treatment and sequencing decisions. The discussion highlights evolving definitions of high-risk disease, the clinical integration of combination EGFR-targeted regimens, and innovations such as subcutaneous amivantamab delivery and ctDNA monitoring, emphasizing the translation of trial evidence into practical, patient-centered oncology care